|
SUNDAY,
MARCH 17, 2002
Late-Breaking
Trials in Interventional Cardiology (#22)
8:45
a.m.
Effect
of Stent Design and Strut Thickness on Long-Term Outcome of
Coronary Stent Placement Results From the ISAR-STEREO-2 Trial—Dr.
Helmut Schühlen, of the German Heart Center in Munich,
Germany
8:58
a.m.
Acute
Myocardial Infarction Study of Adenosine (AMISTAD II)—Dr.
Allan M. Ross, of George Washington University Medical Center,
in Washington, D.C.
9:10
a.m.
Coronary
Artery Stenting: A 1,000-Patient, Prospective, Randomized,
Controlled Trial Comparing a Predilatation With a No-Predilatation
Strategy—Dr.
Keith D. Dawkins, of Wessex Cardiac Unit, Southampton in the
United Kingdom
9:22
a.m.
**Safety
and Feasibility of a Tacrolimus-Coated Drug- Eluting Stent:
Short- and Mid-Term Results of Both the PRESENT and the EVIDENT
Trial—Prof.
Eberhard Grube, of the Heart Centre Siegburg in Germany
9:34
a.m.
A
Randomized Comparison of the MULTI-LINK™ Stent With or
Without Adjunctive Directional Coronary Atherectomy in Coronary
Artery Lesion (AMIGO)—Dr.
Antonio Colombo, of Centro Cuore Columbus
in Milan, Italy
9:46
a.m.
**Heparin-Coated
Stents in Small Coronary Arteries: Results of the COAST Trial—Dr.
Michael Haude, of University Essen in Essen, Germany
MONDAY,
MARCH 18, 2002
Late-Breaking
Clinical Trials I (#405)
9:15
a.m.
**
Two
atrial fibrillation treatments compared in the largest-ever
trial of its kind—Dr.
D. George Wyse, of the University of Calgary in Alberta, Canada
9:30
a.m.
**
Repeated
shocks vs. rate-controlling medications in patients with atrial
fibrillation—Dr.
Harry J. Crijns, of the University Hospital Maastricht in
The Netherlands
9:45
a.m.
Antibiotic/anti-inflammatory
tested in patients with acute unstable chest pain or heart
attack—Dr.
Cercek, of Cedars-Sinai Medical Center in Los Angeles
10:00
a.m.
Can
an antibiotic help prevent second heart attacks in C. pneumoniae
positive patients?—Dr.
Michael W. Dunne, of Pfizer Inc.
10:15
a.m.
Blood thinners compared
in patients getting “super aspirin” for threatened
heart attack—Dr.
Shaun G. Goodman, of St. Michael’s Hospital in Toronto,
Canada
TUESDAY,
MARCH 19, 2002
Late-Breaking
Clinical Trials II (#412)
8:30 a.m.
**
Shock
implants better than drugs alone at preventing heart-rhythm
death after heart attack—Dr.
Arthur J. Moss of the University of Rochester in New York
8:48
a.m.
“Definitive”
trial tests novel vasodilator in patients with heart failure—Dr.
Milton Packer, of Columbia Presbyterian Medical Center in
New York City
9:06
a.m.
Patients
who can benefit most from heart-pump implants may be identifiable—Dr.
Lynne Warner Stevenson, of Brigham and Women’s Hospital
in Boston
9:23
a.m.
**
Bedside test is the
fastest yet at the emergency diagnosis of heart failure—Dr.
Peter A. McCullough, of the University of Missouri-Kansas
City School of Medicine
9:41
a.m.
Breath Test Could Simplify
Monitoring for Tissue Rejection in Heart Transplant Patients—Dr.
Michael Phillips, of Menssana Research, Inc., in Fort Lee,
N.Y.
WEDNESDAY, MARCH 20, 2002
Late-Breaking
Clinical Trials III (#421)
8:30 a.m.
Heartbeat-correcting
implant safely improves lives of heart failure patients—Dr.
James B. Young, of the Cleveland Clinic Foundation, Cleveland,
Ohio
8:48
a.m.
**
Do statin drugs protect
the heart after a patient’s first angioplasty?—Dr.
Serruys, of the Thoraxcenter, Erasmus University Hospital,
Rotterdam, The Netherlands
9:06
a.m.
Randomized
study is the largest ever in patients with a major hypertension
complication—Dr.
Björn Dahlöf, University of Göteborg and Ostra
University Hospital, Göteborg, Sweden
9:23
a.m.
Clot-busters
vs. stents for heart attack: New data on a key issue may be
conclusive—Dr.
Henning R. Andersen, of Skejby University Hospital in Aarhus,
Denmark
9:41
a.m.
Novel
drug combination reverses heart-muscle thickening caused by
high blood pressure—Dr.
Bertram Pitt, University of Michigan, Ann Arbor
**
OVERTURE study could
dramatically reshape heart failure therapy
|
